Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websiteamarincorp.com
CategoryBioTech
Phone+353 (0)1 6699 020
Employees

Offices

Ballsbridge, IRL
First Floor, Block 3, The Oval,
Shelbourne Road, Dublin 4,
Ballsbridge, IRL

People

CFO
President and CEO
Board Member
Board of Directors
Board of Directors
Board of Director
Chief Medical Officer
Boards
Executive Chairman and Chief Executive Officer

Funding

TOTAL $70M
FUNDING TOTAL $70M
Private Equity, 10/2009
Fountain Healthcare Partners
$70M

Tags

Amarin

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin’s lead candidate, AMR101, is currently being studied in two concurrently run pivotal Phase 3 trials. These trials are investigating the efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides (>500mg/dl) and in patients with mixed dyslipidemia who are taking statins. Amarin’s cardiovascular programs capitalize on Amarin’s expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. Amarin is headquartered in Dublin, Ireland, and has its research and development headquartered in Mystic Connecticut, USA. Amarin is listed in the U.S. on NASDAQ (ticker: AMRN)

Recent Milestones

  • Check
    Amarin — has named Paul Huff, an industry veteran with cholesterol drug commercialization under his belt, as chief commercial officer (2/2/11)
    Posted 2/3/11 at 3:54am via masshightech.com
  • Check
    Amarin — has announced a planned $100.2 million financing stemming from a public offering of American Depositary Shares (1/7/11)
    Posted 1/10/11 at 6:50am via masshightech.com
  • Check
    Amarin — has announced a planned $100.2 million financing stemming from a public offering of American Depositary Shares (1/7/11)
    Posted 1/10/11 at 6:50am via masshightech.com
  • Check
    Amarin — reporting positive, statistically significant top-line results from its first Phase 3 clinical trial of lead drug candidate AMR101 (11/29/10)
    Posted 11/30/10 at 6:16am via masshightech.com
  • Check
    Amarin added Joseph S. Zakrzewski as Executive Chairman and Chief Executive Officer. (1/1/10)
    Posted 10/2/13 at 7:50am
  • Dollar
    Amarin received $70M in Private Equity funding. (10/13/09)
    Posted 4/5/14 at 1:04am
  • Check
    Amarin added Dr. Declan Doogan as Chief Medical Officer. (10/1/09)
    Posted 5/10/13 at 2:07am
  • Check
    Amarin added Colin Stewart as President and CEO.
    Posted 8/18/10 at 6:14pm
  • Check
    Amarin added John Thero as CFO.
    Posted 8/18/10 at 6:14pm
  • Check
    Amarin added Lars G. Ekman as Lead Independent Director of the Board.
    Posted 4/14/14 at 3:27am

Videos

Screenshots

Sources

  1. Citation Needed [add]
  2. Amarin treatment for high triglycerides shows progress in trials (masshightech.com) [edit]
    Amarin expecting $100M financing (masshightech.com) [edit]
    Amarin expecting $100M financing (masshightech.com) [edit]
    Amarin names Huff to lead cholesterol drug commercialization (masshightech.com) [edit]
Edit This Page
Last Edited 4/14/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy